Lakewood-Amedex Biotherapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Lakewood-Amedex Biotherapeutics Inc. (LABT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -0.30% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-09-18
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2025-12-31 | -0.30% S-1 · filed 2026-09-18 |
| 2024-12-31 | -0.80% S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B |